751 related articles for article (PubMed ID: 25552421)
1. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Udell JA; Bhatt DL; Braunwald E; Cavender MA; Mosenzon O; Steg PG; Davidson JA; Nicolau JC; Corbalan R; Hirshberg B; Frederich R; Im K; Umez-Eronini AA; He P; McGuire DK; Leiter LA; Raz I; Scirica BM;
Diabetes Care; 2015 Apr; 38(4):696-705. PubMed ID: 25552421
[TBL] [Abstract][Full Text] [Related]
2. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
[TBL] [Abstract][Full Text] [Related]
3. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Price DL; Chen R; Udell J; Raz I
Am Heart J; 2011 Nov; 162(5):818-825.e6. PubMed ID: 22093196
[TBL] [Abstract][Full Text] [Related]
4. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
Mosenzon O; Leibowitz G; Bhatt DL; Cahn A; Hirshberg B; Wei C; Im K; Rozenberg A; Yanuv I; Stahre C; Ray KK; Iqbal N; Braunwald E; Scirica BM; Raz I
Diabetes Care; 2017 Jan; 40(1):69-76. PubMed ID: 27797925
[TBL] [Abstract][Full Text] [Related]
5. Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705.
Kalra S; Gupta Y; Baruah MP; Gupta A
Diabetes Care; 2015 Jun; 38(6):e88-9. PubMed ID: 25998303
[No Abstract] [Full Text] [Related]
6. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Scirica BM; Braunwald E; Raz I; Cavender MA; Morrow DA; Jarolim P; Udell JA; Mosenzon O; Im K; Umez-Eronini AA; Pollack PS; Hirshberg B; Frederich R; Lewis BS; McGuire DK; Davidson J; Steg PG; Bhatt DL;
Circulation; 2014 Oct; 130(18):1579-88. PubMed ID: 25189213
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c.
Cavender MA; Scirica BM; Raz I; Steg PG; McGuire DK; Leiter LA; Hirshberg B; Davidson J; Cahn A; Mosenzon O; Im K; Braunwald E; Bhatt DL
Am J Med; 2016 Mar; 129(3):340.e1-8. PubMed ID: 26524706
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.
Scirica BM; Mosenzon O; Bhatt DL; Udell JA; Steg PG; McGuire DK; Im K; Kanevsky E; Stahre C; Sjöstrand M; Raz I; Braunwald E
JAMA Cardiol; 2018 Feb; 3(2):155-163. PubMed ID: 29214305
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.
Leiter LA; Teoh H; Braunwald E; Mosenzon O; Cahn A; Kumar KM; Smahelova A; Hirshberg B; Stahre C; Frederich R; Bonnici F; Scirica BM; Bhatt DL; Raz I;
Diabetes Care; 2015 Jun; 38(6):1145-53. PubMed ID: 25758769
[TBL] [Abstract][Full Text] [Related]
10. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
[TBL] [Abstract][Full Text] [Related]
11. [SAVOR TIMI 53 - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus].
Spinar J; Smahelová A
Vnitr Lek; 2013 Nov; 59(11):1003-7. PubMed ID: 24279445
[TBL] [Abstract][Full Text] [Related]
12. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial.
Mosenzon O; Wei C; Davidson J; Scirica BM; Yanuv I; Rozenberg A; Hirshberg B; Cahn A; Stahre C; Strojek K; Bhatt DL; Raz I
Diabetes Care; 2015 Nov; 38(11):2142-50. PubMed ID: 26358285
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial.
Briggs AH; Bhatt DL; Scirica BM; Raz I; Johnston KM; Szabo SM; Bergenheim K; Mukherjee J; Hirshberg B; Mosenzon O
Diabetes Res Clin Pract; 2017 Aug; 130():24-33. PubMed ID: 28554140
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).
Gutierrez JA; Scirica BM; Bonaca MP; Steg PG; Mosenzon O; Hirshberg B; Im K; Raz I; Braunwald E; Bhatt DL
Am J Cardiol; 2019 Jan; 123(1):145-152. PubMed ID: 30366601
[TBL] [Abstract][Full Text] [Related]
16. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Raz I; Bhatt DL; Hirshberg B; Mosenzon O; Scirica BM; Umez-Eronini A; Im K; Stahre C; Buskila A; Iqbal N; Greenberger N; Lerch MM
Diabetes Care; 2014 Sep; 37(9):2435-41. PubMed ID: 24914244
[TBL] [Abstract][Full Text] [Related]
17. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
Nowicki M; Rychlik I; Haller H; Warren ML; Suchower L; Gause-Nilsson I;
Diabetes Obes Metab; 2011 Jun; 13(6):523-32. PubMed ID: 21332627
[TBL] [Abstract][Full Text] [Related]
18. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.
Leiter LA; Teoh H; Mosenzon O; Cahn A; Hirshberg B; Stahre CA; Hoekstra JB; Alvarsson M; Im K; Scirica BM; Bhatt DL; Raz I;
Diabetes Obes Metab; 2016 Feb; 18(2):186-90. PubMed ID: 26443993
[TBL] [Abstract][Full Text] [Related]
19. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
20. Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial.
Cahn A; Raz I; Mosenzon O; Leibowitz G; Yanuv I; Rozenberg A; Iqbal N; Hirshberg B; Sjostrand M; Stahre C; Im K; Kanevsky E; Scirica BM; Bhatt DL; Braunwald E
Diabetes Care; 2016 Aug; 39(8):1329-37. PubMed ID: 27222508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
